ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Science

Japan greenlights clinical tests on donor iPS cell transplants

Alternative treatment seen slashing cost, time

Researchers are optimistic that iPS cells will play a major role in regenerative medicine.

TOKYO -- The Japanese health ministry on Wednesday approved clinical research on a regenerative treatment that utilizes donated stem cells.

In treating a degenerative eye disorder in the past, researchers used induced pluripotent stem (iPS) cells harvested from the patient's own body. Employing donated cells will likely reduce the cost and time of the procedure by about 90%.

The government-affiliated Riken research institute, Kyoto University, Osaka University and the Kobe City Medical Center General Hospital will carry out the study. Masayo Takahashi, the project leader for Riken, and others explained Wednesday to a health ministry panel that there are no concerns that iPS or other cells will turn cancerous.

The ministry determined that the proposed clinical research satisfied safety requirements. It will officially sign off on the project as early as this week. Researchers aim to begin surgeries in the first half of this year.

The study will cover about five patients suffering from age-related macular degeneration, an intractable eye disease that could lead to blindness. About 1% of people aged 50 or over in Japan suffer from the disease -- the fourth-leading cause of blindness in the country and the No. 1 cause in the West.

Kyoto University will provide Riken with the iPS cells that will be grown into retinal cells. Osaka University and the Kobe medical center will perform the surgeries. A solution containing the retinal cells will be injected into the back of the patients' eyes.

The iPS cells Kyoto University stores have qualities resistant to immunological rejection. The coming clinical research is not expected to employ immunosuppressant agents. The researchers say expenses will be limited to millions of yen and the time between differentiation of the iPS cells to the transplant could be shortened to as little as one month.

In 2014, Riken and others performed the world's first retinal transplant treating age-related macular degeneration with iPS cells. Those cells came from the patient's body. The process cost roughly 100 million yen ($881,000), which included tests for cancer. The approximately 10-month preparatory period is also seen as a barrier to widespread adoption.

Japan is laying the groundwork for clinical application of iPS treatment outside of macular degeneration. Kyoto University is looking for a cure for Parkinson's disease, Osaka University is focusing on heart and corneal diseases, and Keio University is tackling spinal cord injuries. Last month Kyoto University temporarily halted the provision of iPS cells to outside parties due to possible reagent error, but that freeze will reportedly not affect the joint clinical research.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media